BFRI: Biofrontera Inc Price-to-Revenue Coefficient

Biofrontera Inc. (BFRI) is managed by a team focused on the commercial success of dermatology while maintaining strict adherence to global compliance. The company is expanding its medical presence by supplying equipment and pharmaceuticals for skin cancer therapy. The price-to-sales ratio exhibits sideways movement, with the parameter value reaching 0.30. Stable demand in clinics and strong margins create a reliable cash flow.

BFRI biofrontera-us.com P/S Multiple (07/04/2022 - 11/13/2026)

Metric breakdowns and analytics for Biofrontera Inc. (BFRI)

- current price and projected stock value:

Price Chart biofrontera-us.com|BFRI - Analyst Consensus Forecast

- market capitalization information:

Market Capitalization Biofrontera Inc|BFRI - Total Company Value

- company book value details:

Net Asset Value per Share Biofrontera|BFRI - Book Capitalization|Market Capitalization to Net Assets biofrontera-us.com|BFRI - Aggregate Company Assets

- issuer credit burden and liquidity indicators:

- earnings and multiples data:

BFRI - Company Net Income|Expected Net Income Biofrontera Inc.|BFRI - P/E Multiple|Forward P/E Multiple biofrontera-us.com|BFRI - Price/Earnings to Growth Multiple|Business Value to Operating Income Before Depreciation Biofrontera Inc|BFRI - Operating profit EBITDA|Net earnings per share for the last four quarters Biofrontera|BFRI - Earnings per share for the last twelve months|Year-over-year earnings per share growth for the last 12 months biofrontera-us.com|BFRI - Earnings growth in current year|Expected earnings per share growth for next year Biofrontera Inc.

- issuer revenue and sales details:

BFRI - Company Sales|Company Future Sales biofrontera-us.com|BFRI - P/S Multiple|Price-to-Projected Revenue Ratio Biofrontera Inc

Fundamental company analysis:Biofrontera, Inc. (BFRI)

The P/S multiple compares market capitalization to annual revenue, determining the cost of each dollar of sales and the extent to which investors have overvalued the business. The current value of 0.30 reflects market expectations regarding the synergy of the clinic network and the implementation of Ameluz photodynamic therapy, while fluctuations in the P/S multiple allow for an assessment of Biofrontera Inc. (BFRI) valuation stability relative to the commercialization rates of its dermatological patents.

Who Biofrontera Inc. competes with